Results 121 to 130 of about 31,766 (260)

Strengthening Pharmacovigilance in Africa: PhArmacoVigilance Africa (PAVIA)

PhArmacoVigilance Africa (PAVIA) is a project that was funded by the European Union under European and Developing Countries Clinical Trials Partnership (EDCTP2) programme (grant number CSA2016S-1627-PAVIA). This was originally planned as a 4-year project to be executed from March 2018 until February 2022 but was granted a 1-year no-cost extension ...
Cobelens, Frank G. J., Nderu, Michelle
openaire   +1 more source

Ethical and Legal Challenges of Partially and Fully Autonomous AI in Healthcare: Reinterpreting Liability and Preserving Trust

Bioethics, EarlyView.
ABSTRACT Artificial intelligence (AI) is increasingly embedded in healthcare in a variety of ways, ranging from semi‐autonomous decision support systems to the various visions of completely autonomous clinical systems. This article explores the ethical and legal issues that accompany this shift and argues that traditional ways of understanding medical ...
Man Teng Iong
wiley   +1 more source

Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ahuja A, Prasad S, Manoharan S, Sen A, Rana R, Mody M, Paras F, Archita A, Shaik S, Mehta K, Manoj R, Mishra P, Mehta S, Kapoor P.   +13 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Tubulointerstitial Nephritis Induced by Adalimumab

Turkish Journal of Nephrology
Yasmine Salem Mahjoubi , Widd Kaabi , Ghozlane Lakhoua , Ahmed Zaiem, Riadh Daghfous , Imen Aouinti, Sihem El Aidli   +6 more
doaj   +1 more source

A 'One Health' cross-sectional analysis of reports of potential antibiotic resistance cases in international pharmacovigilance databases. [PDF]

Front Public Health
Mitchell J, Lundquist P, Westerberg C, Purohit M, Stålsby Lundborg C.   +4 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

A comparison of antibiotic resistance reports in pharmacovigilance databases and conventional surveillance across "One Health". [PDF]

Front Public Health
Mitchell J, Purohit M, Lundquist P, Westerberg C, Stålsby Lundborg C.   +4 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Comparison of patient-reported adverse drug reactions with pharmacovigilance records in gastrointestinal disorders. [PDF]

Bioinformation
Basappa AU, Tallam N, Siddiqui R, Mohan D, Bhise MR, Kutty AM.   +5 more
europepmc   +1 more source